
    
      The purpose of this study is to determine time to disease progression of combination therapy
      with capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continous
      infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer
    
  